Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30726275 | 1.00 | SUV39H2 (0.55) | SUV39H2LMNAMAPTALDH1A1PDK2 | |
| SCHEMBL31342423 | 0.87 | PDK2 (0.53) | SUV39H2LMNAMAPTALDH1A1PDK2 | |
| SCHEMBL12663222 | 0.86 | ABCB1 (0.58) | SUV39H2LMNAMAPTALDH1A1PDK2 | |
| SCHEMBL19459053 | 0.86 | ALK (0.51) | SUV39H2LMNAMAPTALDH1A1PDK2 | |
| SCHEMBL31342653 | 0.86 | ALK (0.51) | SUV39H2LMNAMAPTALDH1A1PDK2 | |
| SCHEMBL1639007 | 0.85 | SUV39H2 (0.60) | SUV39H2LMNAMAPTALDH1A1ALK | |
| SCHEMBL1707770 | 0.85 | MAPT (0.57) | SUV39H2LMNAMAPTALDH1A1PDK2 | |
| SCHEMBL20682511 | 0.85 | LMNA (0.54) | SUV39H2LMNAMAPTALDH1A1PDK2 | |
| SCHEMBL30180045 | 0.85 | MAPT (0.56) | LMNAMAPTALDH1A1PDK2SMN1; SMN2 | |
| SCHEMBL12331686 | 0.85 | MAPT (0.56) | LMNAMAPTALDH1A1PDK2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12558428-B2 | Heterobifunctional compounds and their use in treating disease | HALDA THERAPEUTICS OPCO, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4688149-A1 | IRAK4 PROTACS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-20250281623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4558495-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240374588-A1 | IRAK4 PROTACS | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| WO-2024209044-A1 | IRAK4 PROTACS | ASTRAZENECA AB (SE) | 2024-10-10 | — | — | WO | disclosed |
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
| CN-104968654-A | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD | 2015-10-07 | — | — | CN | disclosed |
| US-9034877-B2 | Bifunctional/polyfunctional dopamine D2/D3 agonist as neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2015-05-19 | — | — | US | disclosed |
| WO-2014006554-A1 | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-01-09 | — | — | WO | disclosed |
| US-20120108815-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | SUV39H2 1808/4885LMNA 4019/4885MAPT 4555/4885 |
| US-12558428-B2 | Heterobifunctional compounds and their use in treating disease | BRCA1, H1-0, FOXM1 | SUV39H2 2046/4885LMNA 1837/4885MAPT 3549/4885 |
| US-20250281623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | VHL, HMBS, BRCA1 | SUV39H2 1423/4885LMNA 4675/4885MAPT 1891/4885 |
| US-20240374588-A1 | IRAK4 PROTACS | IRAK4, IRAK2, IRAK3 | SUV39H2 1642/4885LMNA 1536/4885MAPT 1706/4885 |
| US-20120108815-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | DRD3, DRD2, SLC6A3 | SUV39H2 2479/4885LMNA 1908/4885MAPT 218/4885 |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | SUV39H2 1988/4885LMNA 2005/4885MAPT 2946/4885 |
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | IRAK4, IRAK2, IRAK3 | SUV39H2 1087/4885LMNA 2021/4885MAPT 1801/4885 |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K6 | SUV39H2 4137/4885LMNA 3498/4885MAPT 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.